Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
/in Dendritic Cells, International Publications, Multiple MyelomaProgress in Vaccine Therapies for Breast Cancer
/in Breast Cancer, Dendritic Cells, International PublicationsTargeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Multiple MyelomaThe Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
/in Dendritic Cells, International Publications, Prostate CancerDendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial
/in Breast Cancer, Dendritic Cells, International PublicationsIndividualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
/in Acute Leukemia, Dendritic Cells, International PublicationsEmerging role of immunotherapy in urothelial carcinoma-Advanced disease
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial CarcinomaDendritic cell vaccines for melanoma: past, present and future
/in Dendritic Cells, International Publications, Malignant Melanoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer